drugset / Trial / NCT07343479
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
Phase 2
Not yet recruiting
45 enrolled
Zhejiang Cancer Hospital
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, open-label, multi-center, single-arm clinical trial
Timeline
- Start
- 2026-05-01
- Primary completion
- 2027-06-20
- Completion
- 2029-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 4 mg/kg | — |